Invasive scedosporiosis in lung transplant recipients: A nine-year retrospective study in a tertiary care hospital

Ibáñez-Martínez, Elisa; Solé, Amparó; Cañada-Martínez, Antonio José; Muñoz-Núñez, Carlos Francisco; Pastor, A.; Montull, Beatriz; Falomir-Salcedo, Patricia; Valentín, Amparo; López-Hontangas, José Luís; Pemán, Javier

doi:10.1016/j.riam.2021.06.002

Cited by 7 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-comparative studies have shown a low incidence rate of IA < 5% with either n-AmBd or nebulized lipid formulations of AmB alone, or in association with systemic antifungal prophylaxis [ 18 , 53 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 ] ( Supplementary Tables S4 and S5 ). The use of n-AmBd resulted in a significant decrease in IA incidence in several prospective and retrospective studies, in comparison with historical controls without antifungal prophylaxis [ 4 , 117 , 118 , 119 , 120 ].…”

Section: Resultsmentioning

confidence: 99%

Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections

et al. 2022

View full text Add to dashboard Cite

Pulmonary mold infections are life-threatening diseases with high morbi-mortalities. Treatment is based on systemic antifungal agents belonging to the families of polyenes (amphotericin B) and triazoles. Despite this treatment, mortality remains high and the doses of systemic antifungals cannot be increased as they often lead to toxicity. The pulmonary aerosolization of antifungal agents can theoretically increase their concentration at the infectious site, which could improve their efficacy while limiting their systemic exposure and toxicity. However, clinical experience is poor and thus inhaled agent utilization remains unclear in term of indications, drugs, and devices. This comprehensive literature review aims to describe the pharmacokinetic behavior and the efficacy of inhaled antifungal drugs as prophylaxes and curative treatments both in animal models and humans.

show abstract

Section: Resultsmentioning

confidence: 99%

Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The widespread use of azoles as pesticides in the agriculture industry, as well as for antifungal prophylaxis among immunocompromised patients, is also selecting for emerging fungi that display intrinsic resistance against common antifungal agents [6 ▪▪ ,7]. Under the selective pressure of triazole agents, the epidemiology of invasive fungal infections among stem cell and solid organ transplant recipients (namely lung allografts) has begun to shift from Candida and Aspergillus to azole-resistant molds such as Fusarium , Scedosporium and Lomentospora [8,9].…”

Section: Epidemiologymentioning

confidence: 99%

Lung infections due to emerging fungal pathogens

Machiavello Roman,

Pischel,

Azar

2024

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of review This review highlights the epidemiology, pathogenesis and clinical management of pulmonary infections caused by emerging fungal organisms. Recent findings Emerging fungal infections have arisen as a result of population and environmental changes. An enlarging pool of immunocompromised hosts on triazole antifungal prophylaxis has led to an increased incidence of non-Aspergillus molds, such as Fusarium, Scedosporium and Lomentospora spp. Advances in diagnostic capabilities led to the identification of the Emergomyces genus and non-dermatitidis Blastomyces species, which have a significant disease burden in Africa and the Middle East. Climate change has contributed to changing the distribution of previously confined endemic mycoses, like coccidioidomycosis and talaromycosis. These emerging organisms pose important diagnostic and therapeutic challenges. Summary Newly recognized pathogenic fungi and established endemic mycoses with expanding geographic boundaries have become important agents of pulmonary disease. There is a dearth of clinical evidence on the appropriate management of these infections.

show abstract

“…Emerging molds like Scedosporium apio- spermum complex and L. prolificans are a major concern due to the high rate of dissemination and poor outcomes due to high rate of therapeutic failures and relapses. In particular, L. prolificans panresistant strains have elevated mortality rates of up to 95% in disseminated forms [32 ▪ ,33,34 ▪ ].…”

Section: Mould Infections: Aspergillus Scedosporium Spp and Lomentosp...mentioning

confidence: 99%

“…Of the latter, those caused by Scedosporium spp. and L. prolificans are the most frequent and related to poor outcome [12,29–31,32 ▪ ].…”

Section: Mould Infections: Aspergillus Scedosporium Spp and Lomentosp...mentioning

confidence: 99%

Multiresistant organisms: bacteria and beyond

Solé¹

2022

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of reviewInfections with multiresistant organisms are an emerging problem, cause early mortality post lung transplantation and are sometimes associated with graft dysfunction. Frequently they raise questions about the selection of lung transplant candidates and therapeutic management post lung transplantation. There are no guidelines and management must be individualized. This review summarizes the available therapeutic options in cases of multidrug-resistant (MDR) organisms and outcomes after lung transplant.Recent findingsImprovements in diagnosis, new and more effective drugs and the experience gained in the management of these infections in lung transplantation, lead to a more optimistic horizon than that found a decade ago.SummaryUpdate on the management of Burkholderia cepacia complex, Mycobacterium abscessus complex, Aspergillus spp., Scedosporium spp. and Lomentospora prolificans infections. This review clarifies current posttransplant outcomes and adds a little hope in these scenarios.

show abstract

Invasive scedosporiosis in lung transplant recipients: A nine-year retrospective study in a tertiary care hospital

Cited by 7 publications

References 17 publications

Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections

Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections

Lung infections due to emerging fungal pathogens

Multiresistant organisms: bacteria and beyond

Contact Info

Product

Resources

About